News room - Egetis Therapeutics

20 October, 2016 Interim report January - September 2016 News English Report Interim IR Optional

25 August, 2016 Interim report January - June 2016 News Corporate Information Other Corporate Information English IR Optional

25 August, 2016 Interim report January - June 2016 News English Report Interim IR Optional

7 June, 2016 PledPharma reports constructive meeting with the European Medicines Agency (EMA) News English IR Optional

19 May, 2016 PledPharma to present the Phase IIb PLIANT study data at ASCO 2016 News English IR Optional

16 May, 2016 New data strengthens claim that PledOx® does not negatively interfere with the anti-cancer effect of chemotherapy News English IR Optional

29 April, 2016 Interim report first quarter 2016 News English Report Interim Q1 IR Optional

14 April, 2016 Presentation from the AGM is now available on the company's website News English IR Optional

29 February, 2016 Year end report 2015 News English Report Interim Yearend IR Optional

1 December, 2015 PLEDPHARMA PRESENTS NEW IN-DEPTH FOLLOW-UP DATA FROM PLIANT STUDY - PLEDOX® SHOWN TO REDUCE CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY BY 75 PERCENT News English IR Optional

19 November, 2015 PLEDPHARMA REPORTS CONSTRUCTIVE MEETING WITH THE FDA AND PRESENTS NEW FOLLOW-UP DATA News English IR Optional

11 November, 2015 Nomination Committee for the 2016 Annual General Meeting in PledPharma AB News English IR Optional

20 October, 2015 Interim report third quarter 2015 News English Report Interim Q3 IR Optional

22 September, 2015 KEY COMPOUND PATENT FOR PLEDOX® AND ALADOTE® SET TO GAIN US APPROVAL News English IR Optional

18 August, 2015 Interim report second quarter 2015 News English Report Interim Q2 IR Optional

26 June, 2015 PLEDPHARMA PRESENTS ADDITIONAL RESULTS FROM A PHASE IIB STUDY WITH PLEDOX® AT THE SCIENTIFIC CONFERENCE MASCC News English IR Optional

21 April, 2015 Interim report first quarter 2015 News English Report Interim Q1 IR Optional

29 March, 2015 PLEDPHARMA PRESENTS TOP-LINE RESULTS FROM ITS PHASE IIb STUDY – PLEDOX® REDUCES NERVE DAMAGE IN CONJUNCTION WITH CHEMOTHERAPY BY 43 PERCENT News English IR Optional

17 February, 2015 Year-end report 2014 News English Report Interim Yearend IR Optional

17 December, 2014 PledPharma’s rights issue oversubscribed by 34 percent News English IR Optional

14 November, 2014 More than 50 percent of the owners confirm subscription commitments in PledPharma’s planned rights issue News English IR Optional

24 October, 2014 PledPharma AB - Interim report third quarter 2014 News English Report Interim Q3 IR Optional

24 October, 2014 PledPharma presents a new project against acetaminophen-induced poisoning, aimed to be financed by a rights issue News English IR Optional

21 October, 2014 The PLIANT study is fully recruited and the final futility analysis approved News English IR Optional

12 September, 2014 Information video about PLIANT study available News English IR Optional

Press releases